Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice.

Interconnected, fundamental aging processes are central to many illnesses and diseases. Cellular senescence is a mechanism that halts the cell cycle in response to harmful stimuli. Senescent cells (SnCs) can emerge at any point in life, and their persistence, along with the numerous proteins they secrete, can negatively affect tissue function. Interventions aimed at combating persistent SnCs, which can destroy tissues, have been used in preclinical models to delay, halt, or even reverse various diseases. Consequently, the development of small-molecule senolytic medicines designed to specifically eliminate SnCs has opened potential avenues for the prevention or treatment of multiple diseases and age-related issues in humans. In this review, we explore the most promising approaches for translating small-molecule senolytics and other interventions targeting senescence in clinical practice. This discussion highlights the rationale for considering SnCs as therapeutic targets for diseases affecting individuals of all ages. Copyright © 2024 Elsevier B.V. All rights reserved.

Citation

Peng Chen, Yulai Wang, Benhong Zhou. Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice. Mechanisms of ageing and development. 2024 Apr;218:111918

Mesh Tags

Substances

PMID: 38401690

search → result